Tassos Gianakakos
Chief Executive Officer chez MYOKARDIA, INC.
Fortune : 117 331 $ au 31/03/2024
Profil
Actuellement, Anastasios E. Gianakakos occupe le poste de directeur général de MyoKardia, Inc. Il est également membre du conseil d'administration de LianBio. Dans le passé, M. Gianakakos a été président et premier vice-président chargé du développement commercial chez Codexis, Inc, ingénieur des procédés chez Merck & Co, Inc, directeur chargé du développement commercial chez Maxygen, Inc et directeur commercial et premier vice-président chez MAP Pharmaceuticals LLC. Il a obtenu un diplôme de premier cycle au Massachusetts Institute of Technology, un diplôme d'études supérieures à la Northwestern University et un MBA à la Harvard Business School.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
LIANBIO
0,35% | 15/02/2024 | 363 253 ( 0,35% ) | 117 331 $ | 31/03/2024 |
Postes actifs de Tassos Gianakakos
| Sociétés | Poste | Début |
|---|---|---|
| MYOKARDIA, INC. | Chief Executive Officer | 01/10/2013 |
| LIANBIO | Director/Board Member | 01/08/2020 |
Prolaio, Inc.
 Prolaio, Inc. BiotechnologyHealth Technology Prolaio, Inc. is a company founded in 2021 that engages in research and development of medical. The company is based in Scottsdale, AZ. | President | - |
Anciens postes connus de Tassos Gianakakos
| Sociétés | Poste | Fin |
|---|---|---|
MAP Pharmaceuticals LLC
 MAP Pharmaceuticals LLC Medical SpecialtiesHealth Technology MAP Pharmaceuticals, Inc. develops therapies and inhalation delivery technologies. The company was founded by Thomas A. Armer on July 3, 2003 and is headquartered in Irvine, CA. | Corporate Officer/Principal | 01/03/2013 |
| MERCK & CO., INC. | Chief Tech/Sci/R&D Officer | 01/01/1997 |
| CODEXIS, INC. | President | - |
Maxygen, Inc.
 Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | Corporate Officer/Principal | - |
Formation de Tassos Gianakakos
| Massachusetts Institute of Technology | Undergraduate Degree |
| Northwestern University | Graduate Degree |
| Harvard Business School | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| CODEXIS, INC. | Process Industries |
| LIANBIO | Health Technology |
| Entreprise privées | 4 |
|---|---|
Maxygen, Inc.
Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | Commercial Services |
MAP Pharmaceuticals LLC
MAP Pharmaceuticals LLC Medical SpecialtiesHealth Technology MAP Pharmaceuticals, Inc. develops therapies and inhalation delivery technologies. The company was founded by Thomas A. Armer on July 3, 2003 and is headquartered in Irvine, CA. | Health Technology |
MyoKardia, Inc.
 MyoKardia, Inc. Pharmaceuticals: MajorHealth Technology MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA. | Health Technology |
Prolaio, Inc.
Prolaio, Inc. BiotechnologyHealth Technology Prolaio, Inc. is a company founded in 2021 that engages in research and development of medical. The company is based in Scottsdale, AZ. | Health Technology |
